Tag Archive for: Coherus

Junshi Biosciences and Coherus BioSciences unveiled data from the Phase III HEPATORCH study, showing that its PD-1 inhibitor Loqtorzi (toripalimab)—when used with bevacizumab—significantly improved survival in patients with advanced hepatocellular carcinoma.

For Sandoz, Monday’s deal with Coherus represents its first major contract since spinning out of Novartis in October 2023.